We created a stakeholder engagement roadmap to support the launch of a neuro-rare disease pipeline for a new entrant to the rare disease space

Our client needed to understand the best practices for engaging stakeholders in neuro-rare disease to optimise payer decision-making

The client, with no prior experience in rare disease assets, had recently acquired several and aimed to position themselves as a leader in the neuro-rare space. However, their market access team lacked the
expertise needed to successfully launch rare disease treatments and optimise PRMA outcomes

The client needed to understand:

• Optimal engagement methods, objectives, channels and timing
• The best practices for varying disease epidemiology, unmet medical need and payer awareness